Scaling up Xpert MTB/RIF technology: the costs of laboratory- vs. clinic-based roll-out in South Africa.
about
Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adultsXpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adultsPoint-of-care diagnosis of tuberculosis: past, present and futurePopulation health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB/RIF: a dynamic simulation and economic evaluationTime to treatment and patient outcomes among TB suspects screened by a single point-of-care xpert MTB/RIF at a primary care clinic in Johannesburg, South AfricaAlignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for actionPoint-of-care testing for infectious diseases: diversity, complexity, and barriers in low- and middle-income countries.State of affairs of tuberculosis in prison facilities: a systematic review of screening practices and recommendations for best TB controlThe hidden costs of installing Xpert machines in a tuberculosis high-burden country: experiences from Nigeria.Automated chest-radiography as a triage for Xpert testing in resource-constrained settings: a prospective study of diagnostic accuracy and costsCost-effectiveness analysis of microscopic observation drug susceptibility test versus Xpert MTB/Rif test for diagnosis of pulmonary tuberculosis in HIV patients in Uganda.Economic challenges associated with tuberculosis diagnostic development.Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care testOutcomes of a clinical diagnostic algorithm for management of ambulatory smear and Xpert MTB/Rif negative HIV infected patients with presumptive pulmonary TB in Uganda: a prospective studyUsing Xpert MTB/RIFPerformance monitoring of mycobacterium tuberculosis dried culture spots for use with the GeneXpert system within a national program in South Africa.Cost-effectiveness of Xpert® MTB/RIF for diagnosing pulmonary tuberculosis in the United States.Biomarkers of tuberculosis: a research roadmap.Higher cost of implementing Xpert(®) MTB/RIF in Ugandan peripheral settings: implications for cost-effectiveness.Impact of Point-of-care Xpert MTB/RIF on Tuberculosis Treatment Initiation: A Cluster Randomised Trial.Microscopic observation drug-susceptibility assay vs. Xpert® MTB/RIF for the diagnosis of tuberculosis in a rural African setting: a cost-utility analysis.The laboratory health system and its response to the Ebola virus disease outbreak in Liberia.Compounding diagnostic delays: a qualitative study of point-of-care testing in South Africa.Understanding the incremental value of novel diagnostic tests for tuberculosis.Point-of-care diagnostics to improve maternal and neonatal health in low-resource settings.Robust, reliable and resilient: designing molecular tuberculosis tests for microscopy centers in developing countries.Time-and-motion tool for the assessment of working time in tuberculosis laboratories: a multicentre study.Incremental cost-effectiveness of the second Xpert MTB/RIF assay to detect Mycobacterium tuberculosis.
P2860
Q24200879-ECF33A56-D5DF-4369-85DD-2556E022813AQ24201466-DE03BE2B-BC58-4410-A2AE-DA512F58FFA4Q27004667-2C749738-E70B-406C-9998-6FEA0C384353Q28485280-A7B8D629-3E4F-4AE8-A288-9F51C79B206DQ28533713-C5C0FED7-5B3E-4339-9746-4C25E8D11370Q33576909-C5FBEF62-A1AB-496F-A377-2B122A040E65Q34413592-7773F31B-7115-450A-AC1B-AAE4BBCF62A8Q34570912-0E50D975-EDCE-4EA1-BA7E-3740083ECF82Q34644840-935B8AEC-D443-45D6-BD12-3681537976DCQ35891122-7A6E79B6-0AEB-48EE-8889-27B8866B6C36Q36159840-8B3B4F51-DD5C-4AD8-A5C5-CFB8B9CE0040Q36160928-60F5F837-8A92-4A7E-8BFA-7690F8D0160EQ36833723-CC04EBF8-180B-45F3-9FFC-7A1F4DA3168AQ36973274-CC8D1199-F0C7-46D5-B6B9-1E2043343B26Q37202392-B22C12DF-F487-405C-B895-EEA0BAFD27A1Q37336285-A2360530-1EF9-4F1F-9D98-7E4489963F7EQ37478715-62A7AC69-88A7-46EC-BFC4-05DE8DF6B10FQ38111807-9DEAD556-C432-4C7F-80EC-566810229438Q38853460-9269604E-7182-46D5-81D2-8D209BAA7ADEQ39172214-177F4DDC-8548-4B72-B665-3FF97197DD1DQ39592738-81230E4B-F8D6-4C22-900A-1B315310C8DFQ40040366-FC71F0AD-9227-4916-94AF-214744E55ED8Q40242841-D44AFF53-ADCC-42A0-B833-05ACD18E0657Q40245352-8A3BF593-1660-4560-BEE4-90C5168757FEQ46303043-909D21A0-AA0D-443B-A95D-54810306EDEBQ46949758-CFD67D39-796F-4AF8-A250-30177CE832BDQ52644255-DE043E79-960D-4B8F-A271-28427CD89863Q53690300-8DF4CDAC-4DC9-46B9-AD4E-F77B4AD50853
P2860
Scaling up Xpert MTB/RIF technology: the costs of laboratory- vs. clinic-based roll-out in South Africa.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Scaling up Xpert MTB/RIF techn ...... ased roll-out in South Africa.
@ast
Scaling up Xpert MTB/RIF techn ...... ased roll-out in South Africa.
@en
type
label
Scaling up Xpert MTB/RIF techn ...... ased roll-out in South Africa.
@ast
Scaling up Xpert MTB/RIF techn ...... ased roll-out in South Africa.
@en
prefLabel
Scaling up Xpert MTB/RIF techn ...... ased roll-out in South Africa.
@ast
Scaling up Xpert MTB/RIF techn ...... ased roll-out in South Africa.
@en
P2860
P50
P1476
Scaling up Xpert MTB/RIF techn ...... ased roll-out in South Africa.
@en
P2093
Wendy S Stevens
P2860
P304
P356
10.1111/J.1365-3156.2012.03028.X
P577
2012-06-12T00:00:00Z